JP2022536345A5 - - Google Patents
Info
- Publication number
- JP2022536345A5 JP2022536345A5 JP2021573421A JP2021573421A JP2022536345A5 JP 2022536345 A5 JP2022536345 A5 JP 2022536345A5 JP 2021573421 A JP2021573421 A JP 2021573421A JP 2021573421 A JP2021573421 A JP 2021573421A JP 2022536345 A5 JP2022536345 A5 JP 2022536345A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024216112A JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861651P | 2019-06-14 | 2019-06-14 | |
| US62/861,651 | 2019-06-14 | ||
| US201962947806P | 2019-12-13 | 2019-12-13 | |
| US62/947,806 | 2019-12-13 | ||
| PCT/US2020/037644 WO2020252418A2 (en) | 2019-06-14 | 2020-06-13 | Novel interleukin-2 variants for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024216112A Division JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536345A JP2022536345A (ja) | 2022-08-15 |
| JPWO2020252418A5 JPWO2020252418A5 (https=) | 2023-08-07 |
| JP2022536345A5 true JP2022536345A5 (https=) | 2023-08-07 |
| JP7607938B2 JP7607938B2 (ja) | 2025-01-06 |
Family
ID=73782252
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573421A Active JP7607938B2 (ja) | 2019-06-14 | 2020-06-13 | がんの治療ための新規インターロイキン－２バリアント |
| JP2024216112A Pending JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024216112A Pending JP2025063029A (ja) | 2019-06-14 | 2024-12-11 | がんの治療ための新規インターロイキン－２バリアント |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220235109A1 (https=) |
| EP (1) | EP3983433A4 (https=) |
| JP (2) | JP7607938B2 (https=) |
| KR (1) | KR20220034115A (https=) |
| CN (2) | CN114651004B (https=) |
| AU (1) | AU2020291942B2 (https=) |
| CA (1) | CA3143034A1 (https=) |
| MX (2) | MX2021015834A (https=) |
| WO (1) | WO2020252418A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019028419A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
| WO2020057646A1 (zh) | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| ES3059360T3 (en) | 2018-11-08 | 2026-03-19 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| KR20260039812A (ko) | 2019-02-06 | 2026-03-20 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
| CN114555632A (zh) | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| MX2022002740A (es) | 2019-09-10 | 2022-03-25 | Synthorx Inc | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. |
| WO2022012428A1 (zh) * | 2020-07-14 | 2022-01-20 | 迈威(上海)生物科技股份有限公司 | 抗pd-1抗体及其稳定制剂 |
| EP4208474A2 (en) * | 2020-09-01 | 2023-07-12 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20230124030A (ko) * | 2020-12-23 | 2023-08-24 | 머크 샤프 앤드 돔 엘엘씨 | 자가면역 및 염증성 질환을 치료하기 위한 il-2 뮤테인 |
| US20240262913A1 (en) * | 2021-03-09 | 2024-08-08 | Hoffmann-La Roche Inc. | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies |
| JP2024508949A (ja) * | 2021-03-09 | 2024-02-28 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－１標的化ｉｌ－２変異体イムノコンジュゲートとｆａｐ／４－１ｂｂ結合分子との併用療法 |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| EP4314033A4 (en) * | 2021-03-31 | 2025-04-23 | Anwita Biosciences, Inc. | FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
| CN112724263B (zh) * | 2021-04-02 | 2021-08-03 | 上海偌妥生物科技有限公司 | 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用 |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| US20250002601A1 (en) | 2021-06-09 | 2025-01-02 | Innate Pharma | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
| CA3227386A1 (en) * | 2021-07-28 | 2023-02-02 | Jianing Huang | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications |
| CN113831402A (zh) * | 2021-07-30 | 2021-12-24 | 西安龙腾景云生物科技有限公司 | 一种人白细胞介素2变体及其用途 |
| KR20240082364A (ko) * | 2021-09-22 | 2024-06-10 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 인터루킨-2 돌연변이 및 이의 융합 단백질 |
| US20240417453A1 (en) * | 2021-10-27 | 2024-12-19 | Anwita Biosciences, Inc. | Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications |
| US20250215452A1 (en) | 2022-03-25 | 2025-07-03 | Universität Zürich | Adenoviral Mediated Targeting of Activated Immune Cells |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
| CN120225547A (zh) * | 2022-11-17 | 2025-06-27 | 南通壹宸生物医药科技有限公司 | Il-2突变体及其应用 |
| KR102893442B1 (ko) * | 2022-12-23 | 2025-12-01 | 가톨릭대학교 산학협력단 | 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| EP4689123A1 (en) * | 2023-03-29 | 2026-02-11 | WuXi Biologics Ireland Limited | Il-2 variants with improved stability and compositions thereof |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| WO2025059162A1 (en) * | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2026064732A1 (en) * | 2024-09-23 | 2026-03-26 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| BRPI0508470A (pt) * | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| WO2016025385A1 (en) * | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR102687530B1 (ko) * | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| JP2020536967A (ja) * | 2017-10-12 | 2020-12-17 | イミュノウェイク インコーポレイテッド | Ｖｅｇｆｒ−抗体軽鎖融合タンパク質 |
| JP7637415B2 (ja) * | 2018-06-22 | 2025-02-28 | キュージーン インコーポレイテッド | インターロイキン－２バリアントおよびその使用方法 |
-
2020
- 2020-06-13 CA CA3143034A patent/CA3143034A1/en active Pending
- 2020-06-13 AU AU2020291942A patent/AU2020291942B2/en active Active
- 2020-06-13 EP EP20823471.6A patent/EP3983433A4/en active Pending
- 2020-06-13 JP JP2021573421A patent/JP7607938B2/ja active Active
- 2020-06-13 US US17/618,140 patent/US20220235109A1/en active Pending
- 2020-06-13 MX MX2021015834A patent/MX2021015834A/es unknown
- 2020-06-13 KR KR1020227001353A patent/KR20220034115A/ko active Pending
- 2020-06-13 CN CN202080057527.1A patent/CN114651004B/zh active Active
- 2020-06-13 WO PCT/US2020/037644 patent/WO2020252418A2/en not_active Ceased
- 2020-06-13 CN CN202511005109.9A patent/CN120795117A/zh active Pending
-
2021
- 2021-12-15 MX MX2025014988A patent/MX2025014988A/es unknown
-
2024
- 2024-12-11 JP JP2024216112A patent/JP2025063029A/ja active Pending